We aren’t that close to a treatment for Alzheimer’s disease, unfortunately. Currently we are looking at the interactions between the endoplasmic reticulum and mitochondria, and how they change in Alzheimer’s disease. If we figure out what protein interactions are altered in disease, this interaction could be a new target for drug companies. We can then screen compounds to see if any of them fix the altered interaction. If we identify good compounds, then we can work with drug companies to use that compound (or find a similar drug) to test in animals, and then possibly in humans in clinical trials.
Comments